SG
VRTX icon

Strid Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Strid Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.24M Hold
2,500
– – 0.14% 34
2026
Q1 		$1.12M Hold
2,500
– – 0.14% 34
2025
Q4 		$1.13M Hold
2,500
– – 0.14% 32
2025
Q3 		$979K Hold
2,500
– – 0.12% 36
2025
Q2 		$1.11M Buy
+2,500
New +$1.15M 0.16% 30

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Strid Group's VRTX Position: Q2 2026 in Review

Strid Group held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 2,500 shares worth $1.24M. The position accounts for 0.14% of the portfolio, ranked #34.

Strid Group first reported a position in VRTX in Q2 2025 and has held it in 5 quarters since. 1,756 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Strid Group held 2,500 shares of Vertex Pharmaceuticals worth $1.24M as of Q2 2026.
  • Strid Group left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
  • Vertex Pharmaceuticals made up 0.14% of Strid Group's portfolio in Q2 2026, its #34 holding.
  • Strid Group first reported a position in Vertex Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 1,756 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Strid Group's 13F filing for Q2 2026, filed 23 Jul 2026.